16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Clinical, behavioural and neural validation of the PANSS amotivation factor.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Negative symptoms in schizophrenia have been suggested to map onto two distinct factors - amotivation and diminished expression. Only recently, two-factor solutions for measuring negative symptoms have been proposed for the Positive and Negative Symptom Scale (PANSS), the most commonly used scale to assess the psychopathology of patients with schizophrenia. We aimed to validate the PANSS two-factor structure on a clinical, behavioural and neural level. For this multi-level validation, we reanalysed several datasets with patients for whom both the Brief Negative Symptom Assessment Scale (BNSS) and PANSS data were collected. We used a clinical dataset (n = 120) as well as behavioural data from an effort-based decision making task (n = 31) and functional neuroimaging data from a monetary incentive delay task (n = 41). Both tasks have previously been shown to be associated with BNSS amotivation. On the clinical level, the PANSS amotivation and diminished expression were highly correlated with their BNSS counterparts. On the behavioural level, we found that the PANSS amotivation factor but not the diminished expression factor specifically associated with willingness to invest effort to obtain a reward. On the neural level, PANSS amotivation was specifically related to reduced ventral striatal activation during reward anticipation. Our data confirm that the PANSS clearly allows distinguishing amotivation from diminished expression, as it relates selectively to specific aspects of behaviour and brain function. Our results will allow a re-analysis and sharing of existing datasets that used the PANSS to further substantiate the distinction between the two factors in neuroscientific studies and clinical trials.

          Related collections

          Author and article information

          Journal
          Schizophr Res
          Schizophrenia research
          Elsevier BV
          1573-2509
          0920-9964
          June 2020
          : 220
          Affiliations
          [1 ] Clinical and Experimental Psychopathology Group, Department of Psychiatry, University of Geneva, Switzerland. Electronic address: Mariia.Kaliuzhna@unige.ch.
          [2 ] Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Switzerland; Montreal Neurological Institute, McGill University, Montreal, Canada.
          [3 ] Clinical and Experimental Psychopathology Group, Department of Psychiatry, University of Geneva, Switzerland.
          [4 ] Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Switzerland.
          [5 ] Laboratory for Social and Neural Systems Research, Department of Economics, University of Zurich, Switzerland.
          [6 ] Clinical and Experimental Psychopathology Group, Department of Psychiatry, University of Geneva, Switzerland; Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Switzerland.
          Article
          S0920-9964(20)30225-5
          10.1016/j.schres.2020.04.018
          32349887
          c8b14b8f-8329-4848-876c-52a6a1bae110
          Copyright © 2020 Elsevier B.V. All rights reserved.
          History

          Amotivation,BNSS,Diminished expression,Negative symptoms,PANSS,Schizophrenia

          Comments

          Comment on this article